ATYR Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -13550.53% compared to aTyr Pharma, Inc.'s net margin of -2301.55%. aTyr Pharma, Inc.'s return on equity of -103.05% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

aTyr Pharma, Inc. has a consensus price target of $4.36, signalling upside risk potential of 505.16%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 43.31%. Given that aTyr Pharma, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe aTyr Pharma, Inc. is more attractive than Armata Pharmaceuticals, Inc..

aTyr Pharma, Inc. has a beta of 0.572, which suggesting that the stock is 42.802% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

aTyr Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. aTyr Pharma, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

aTyr Pharma, Inc. quarterly revenues are $190K, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. aTyr Pharma, Inc.'s net income of -$25.7M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, aTyr Pharma, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for aTyr Pharma, Inc. is 345.13x versus 51.01x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Baxter International, Inc. has a net margin of -13550.53% compared to aTyr Pharma, Inc.'s net margin of -1.8%. aTyr Pharma, Inc.'s return on equity of -103.05% beat Baxter International, Inc.'s return on equity of -4.83%.

aTyr Pharma, Inc. has a consensus price target of $4.36, signalling upside risk potential of 505.16%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.67 which suggests that it could grow by 25.02%. Given that aTyr Pharma, Inc. has higher upside potential than Baxter International, Inc., analysts believe aTyr Pharma, Inc. is more attractive than Baxter International, Inc..

aTyr Pharma, Inc. has a beta of 0.572, which suggesting that the stock is 42.802% less volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.771%.

aTyr Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.72% to investors and pays a quarterly dividend of $0.01 per share. aTyr Pharma, Inc. pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.

aTyr Pharma, Inc. quarterly revenues are $190K, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. aTyr Pharma, Inc.'s net income of -$25.7M is higher than Baxter International, Inc.'s net income of -$51M. Notably, aTyr Pharma, Inc.'s price-to-earnings ratio is -- while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for aTyr Pharma, Inc. is 345.13x versus 0.89x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -13550.53% compared to aTyr Pharma, Inc.'s net margin of -12425.36%. aTyr Pharma, Inc.'s return on equity of -103.05% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

aTyr Pharma, Inc. has a consensus price target of $4.36, signalling upside risk potential of 505.16%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that aTyr Pharma, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe aTyr Pharma, Inc. is more attractive than Perspective Therapeutics, Inc..

aTyr Pharma, Inc. has a beta of 0.572, which suggesting that the stock is 42.802% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

aTyr Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. aTyr Pharma, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

aTyr Pharma, Inc. quarterly revenues are $190K, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. aTyr Pharma, Inc.'s net income of -$25.7M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, aTyr Pharma, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for aTyr Pharma, Inc. is 345.13x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -13550.53% compared to aTyr Pharma, Inc.'s net margin of 13.19%. aTyr Pharma, Inc.'s return on equity of -103.05% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

aTyr Pharma, Inc. has a consensus price target of $4.36, signalling upside risk potential of 505.16%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 521.47%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than aTyr Pharma, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than aTyr Pharma, Inc..

aTyr Pharma, Inc. has a beta of 0.572, which suggesting that the stock is 42.802% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

aTyr Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. aTyr Pharma, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

aTyr Pharma, Inc. quarterly revenues are $190K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. aTyr Pharma, Inc.'s net income of -$25.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, aTyr Pharma, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for aTyr Pharma, Inc. is 345.13x versus 2.25x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.